PolyPid regained Europe rights: what it meant for PolyPid stock

Published on 10/14/2026 at 00:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The October 1 move restored European rights for D-PLEX100. For PolyPid stock this means a 60.00 percent trial risk reduction.

Regulatory dates and trial evidence

European rights returned to PolyPid on October 1, 2026 after the Advanz Pharma agreement ended.
The EMA validated the D-PLEX100 application on October 1, 2026.
The FDA decision carries a November 28, 2026 PDUFA goal date.
PolyPid management is scheduled to meet Craig-Hallum on October 21, 2026.

PYPD, IL0011326795, Illustration mit AI erstellt.

PolyPid (ISIN IL0011326795) regained European commercialization rights for D-PLEX100 on October 1, 2026, after ending its 2022 agreement with Advanz Pharma, according to The Globe and Mail. The strategic value depends on regulatory execution, with the FDA decision for D-PLEX100 carrying a November 28, 2026 PDUFA goal date.

Three regulatory steps since September

PolyPid submitted its European marketing application on September 14, 2026 under the centralized procedure, according to PolyPid. On October 1, the European Medicines Agency validated the application and began formal review. The same date marked the return of exclusive European commercialization rights after the 2022 license, distribution and supply agreement ended, as The Globe and Mail reported.

What does the trial mean?

The Phase 3 SHIELD II trial reported a 60.00 percent relative risk reduction in surgical site infections compared with standard care, with a p-value of 0.0013, according to PolyPid. D-PLEX100 is designed to deliver doxycycline locally for 30 days, giving the company a clinical result and a defined product profile as regulators review the applications.

Upcoming dates for PolyPid

Two dates shape the next phase. Markets Insider reported that PolyPid management is scheduled to meet virtually with Craig-Hallum on October 21, 2026. A quarterly update is listed for November 11, 2026 by Wallstreet Online, followed by the FDA goal date on November 28, 2026.

Regulatory milestones set the timetable

The European review, the November 11 reporting date and the November 28 FDA milestone give PolyPid a sequence of dated tests for D-PLEX100. The company has 72 full-time employees and operates in biotechnology, while its lead candidate remains the central value driver described in the investor materials.

Market context: Market report Nasdaq Composite.